Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Market Update

Julia Lee
November 17, 2016

Peter Quinton on Trump’s victory

Bell Direct
November 17, 2016

Bell Potter: Banks post-results review

Bell Direct
November 11, 2016

mFund series: Peters MacGregor

Bell Direct
October 11, 2016

mFund series: RARE Infrastructure

Bell Direct
October 11, 2016

Bell Potter: Five standout stocks

Bell Direct
October 7, 2016

September newsletter Julia’s insights

Julia Lee
September 29, 2016

mFund series – Schroders

Bell Direct
September 26, 2016